People · Operator

Brad Oleshansky

Named in public records as an officer, director or promoter · active 2014–2016 · Healthtech, Other

2
Companies
3
Filings
$4.5M
Combined raised · real
Serial
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
First Sense Medical, LLCHealthtechSeed$4.4M$39.8M2016
VitaPerk LLCOtherPre-Seed$100K$2.3M2014
Operator network

Brad Oleshansky at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

David Berman · 8 companies · 1 sharedDavid BermanRoger Newton · 4 companies · 1 sharedRoger NewtonAlan Klevens · 1 companies · 1 sharedAlan KlevensAngott G. Paul · 1 companies · 1 sharedAngott G. PaulBrad T. Oleshansky · 1 companies · 1 sharedBrad T. OleshanskyGina T. Fundaro · 1 companies · 1 sharedGina T. FundaroKaren T. Milner · 1 companies · 1 sharedKaren T. MilnerMark T. Mitchell · 1 companies · 1 sharedMark T. MitchellPaul Angott · 1 companies · 1 sharedPaul AngottRoger T. Newton · 1 companies · 1 sharedRoger T. NewtonBrad Kifferstein · 1 companies · 1 sharedBrad KiffersteinBrad Shanahan · 1 companies · 1 sharedBrad ShanahanJeremy Belchinsky · 1 companies · 1 sharedJeremy BelchinskyFirst Sense Medical, LLC · $4.4M raisedFirst Sense Medical, …VitaPerk LLC · $0.1M raisedVitaPerk LLCBrad OleshanskyBO
Brad Oleshansky Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Brad Oleshansky on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
David Berman18
Roger Newton14
Roger T. Newton11
Karen T. Milner11
Brad T. Oleshansky11
Gina T. Fundaro11
Angott G. Paul11
Mark T. Mitchell11
Paul Angott11
Alan Klevens11
Jeremy Belchinsky11
Brad Kifferstein11
Brad Shanahan11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.